

Scientific Program / Programme scientifique

Saturday, July 26 / Le samedi 26 juillet		
13:00 – 17:00	Registration / Inscription	MAIN LOBBY / ENTRÉE PRINCIPALE
Sunday, July 27 / Le dimanche 27 juillet		
10:00 – 20:00	Registration / Inscription	MAIN LOBBY / ENTRÉE PRINCIPALE
13:00 – 17:00	<p>Workshop on Pharmacoeconomics for Decision-Makers / Atelier sur “Pharmacoeconomics for Decision-Makers” <i>Sponsored by / Commandité par : International Society for Pharmaceutical Outcomes Research (ISPOR)</i></p> <p>Speaker: Karen Rascati, University of Texas College of Pharmacy</p>	SALON 2000B
13:00 – 17:00	<p>Workshop on Pharmacoepidemiology / Atelier sur “Pharmacoepidemiology” <i>Sponsored by / Commandité par : International Society for Pharmacoepidemiology (ISPE)</i></p>	SALON 2000A
17:30 – 19:00	Opening Ceremony / Cérémonie d'ouverture	SALON 200 ABC
19:00 – 21:00	Welcome Reception / Réception de bienvenue	EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC
Monday, July 28 / Le lundi 28 juillet		
07:15 – 08:15	<p>Meet-the-Expert Sunrise Sessions Séance « Un expert rencontre les Lève-tôt »</p>	
	<p>GATC - Genomics Approaches to Therapy for Children - The Pharmacogenomics of Adverse Drug Reactions <i>Sponsored by / Commandité par : Child & Family Research Institute</i> Speaker: Bruce Carleton, University of British Columbia</p>	SALON 2000B
07:15 – 08:15	<p>Meet-the-Expert Sunrise Sessions Séance « Un expert rencontre les Lève-tôt »</p>	
	<p>The Clinical Relevance of Pharmacokinetic Changes in Pregnancy M.F. Hebert, University of Washington, Seattle, USA <i>Sponsored by / Commandité par : Canada's Research-Based Pharmaceutical Companies (Rx&D)</i></p>	SALON 2000A
07:30 – 18:00	Registration / Inscription	MAIN LOBBY / ENTRÉE PRINCIPALE
08:30 – 09:30	<p>Plenary / Plénière I: Progress in Cancer Treatment: Molecular Targets L.D. Lewis, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA</p>	SALON 200AB
09:30 – 09:45	Coffee Break / Pause-café	EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC

09:45 – 12:15	Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques
	<p style="text-align: right;">SALON 2000A</p> <p>S01 New Anticancer Drugs and Cancer Treatment in the 21st Century Chaired by / Présidé par : Yasuhiro Fujiwara, National Cancer Center Hospital, Tokyo, Japan Edward A. Sausville, University of Maryland Greenebaum Cancer Center, Baltimore, USA</p> <ul style="list-style-type: none"> • Heat Shock Protein 90 as a Novel Target: Progress and Issues <u>E.A. Sausville</u>, <i>University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, USA</i> • Therapy (DNA Methyltransferase Inhibitor) TBD • Metronomic Low Dose Antiangiogenic Chemotherapy in Mice and Men <u>R.S. Kerbel</u>, <i>Sunnybrook Health Sciences Centre, and University of Toronto, Toronto, Canada</i> • NK1-Receptor Antagonist David G. Warr, Princess Margaret Hospital, Toronto, Canada • Clinical Outcome of S-1: The Fourth Generation of Oral Fluoropyrimidine Masashi Fujii, Nihon University School of Medicine, Tokyo, Japan
09:45 – 12:15	Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique
	<p style="text-align: right;">SALON 2000B</p> <p>S02 Drug Hypersensitivity: Insights into Pathophysiology and Therapy Chaired by / Présidé par : Munir Pirmohammed, Department of Pharmacology, The University of Liverpool, Ashton Street, Liverpool, UK Michael Rieder, CIHR-GSK Chair in Paediatric Clinical Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada</p> <ul style="list-style-type: none"> • Canadian National Active Surveillance Network for Adverse Drug Reactions: Genotypic Adjustment of Therapeutics in Children (GATC) <u>B.C. Carleton</u>^{1,2,3}, C.A. Hildebrand², M.A. Smith², C.J.D. Ross^{3,5}, S.R. Rassekh⁴, M.R. Hayden^{3,5} ¹<i>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada;</i> ²<i>Pharmaceutical Outcomes Programme, Children's and Women's Health Centre of British Columbia, Vancouver, Canada;</i> ³<i>Child & Family Research Institute, Vancouver, Canada;</i> ⁴<i>Paediatric Hematology/Oncology/BMT, Children's and Women's Health Centre of British Columbia, Vancouver, Canada;</i> ⁵<i>Medical Genetics, University of British Columbia, Vancouver, Canada</i> • Bridging Pharmacology with Immunology: The p-i Concept <u>W.J. Pichler</u>, <i>Allergology, Inselspital, University of Bern, CH 3010 Bern, Switzerland</i> • The Chemical Nature of Drug Hypersensitivity <u>J. Uetrecht</u>, <i>University of Toronto, Toronto, Canada</i> • Pharmacogenomics of Hypersensitivity ADRs <u>M. Pirmohammed</u>, <i>Department of Pharmacology, The University of Liverpool, Ashton Street, Liverpool, UK</i> • Immune Mediation of Hypersensitivity ADRs: Implications for Therapy <u>M. Rieder</u>, <i>CIHR-GSK Chair in Paediatric Clinical Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada</i>
09:45 – 12:15	Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société
	<p style="text-align: right;">SALON 2000C</p> <p>S03 Drugs in Sport</p>

09:45 – 12:15	<p>Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers</p>
	<p style="text-align: right;">SALON 2000D</p> <p>S04 Pediatric Clinical Pharmacology at the Dawn of a New Era <i>Sponsored by / Commandité par i3</i> Chaired by / Présidé par : Imti Choonara, University of Nottingham, Derby, UK Stuart MacLeod, Child & Family Research Institute, Vancouver, Canada</p> <ul style="list-style-type: none"> • Is the Sun Really Rising? (Paediatric Clinical Pharmacology in Europe) <i>I. Choonara, University of Nottingham, Derby, UK</i> • The Onset of a New Era <i>Gerard Pons, Cochin - Saint Vincent de Paul Hospital, Paris, France</i> • The Needs of a Billion Asian Children <i>Hidefumi Nakamura, National Center for Child Health and Development, Tokyo, Japan</i> • Challenges in Neonatal Pharmacology <i>John van den Anker, Children's National Medical Center, Washington, USA</i> • Anti-infectives and Child Survival <i>Gabriel Anabwani, Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana</i>
12:15 – 14:00	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Lunch and Poster Viewing / Déjeuner et séance d'affichage</p>
14:00 – 15:00	<p style="text-align: right;">SALON 200AB</p> <p>Plenary / Plénière II : Nanomedicines: Entering the Mainstream <i>T.M. Allen¹, W. Cheng¹, S. Hussain², K. Laghina¹, F. Pastorino³, A. Plückthun⁴, M. Ponzoni³, U. Zangemeister-Wittke^{2,4}, ¹University of Alberta, Edmonton, Canada, ²University of Zurich, Zurich, Switzerland, ³G. Gaslini Children's Hospital, Genoa, Italy, ⁴University of Bern, Bern, Switzerland</i></p>
15:00 – 15:15	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Coffee Break / Pause-café</p>
15:15 – 17:45	<p>Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques</p>
	<p style="text-align: right;">SALON 2000A</p> <p>S05 New Insights in the Treatment of Pain Chaired by / Présidé par : Pierre Beaulieu, Université de Montréal, Montréal, Canada Daniele Piomelli, Department of Pharmacology, University of California, Irvine, USA</p> <ul style="list-style-type: none"> • Mechanism of Action of Acetaminophen and Clinical Implications <i>A. Eschalièr, UMR 766 Inserm/UDA, Clermont-Ferrand, France</i> • Recent Advances in the Treatment of Neuropathic Pain <i>C. Sommer, University of Würzburg, Department of Neurology, Würzburg, Germany</i> • The Endocannabinoid System and the Regulation of Pain, Anxiety and Mood <i>D. Piomelli, Department of Pharmacology, University of California, Irvine, USA</i> • Treatment of Pain and Sleep Interactions <i>P. Beaulieu, Université de Montréal, Montréal, Canada</i> • Tetrodotoxin (TTX): From Poison to Medicine <i>N.A. Hagen¹, B. Lapointe², A.H. Ngoc³, P. du Souich⁴, ¹Tom Baker Cancer Centre and Department of Oncology, University of Calgary, Calgary, Canada; ²Palliative Care Medicine, Department of Oncology, Jewish Hospital, McGill University, Montréal, Qc, Canada; ³Wex Pharmaceuticals Inc., Vancouver, Canada; ⁴Department de Pharmacology, University de Montréal, Montréal, P.Q, Canada</i>

15:15 – 17:45	<p>Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique</p>
	<p style="text-align: right;">SALON 2000B</p> <p>S06 Drug Transport and Metabolism in the Brain: Potential Roles in Clinical Pharmacology Chaired by / Présidé par : Rachel Tyndale, Centre for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, Canada Reina Bendayan, Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada</p> <ul style="list-style-type: none"> • Physical and Biochemical Barriers to Drug Transport in the Brain <u>R. Bendayan</u>, <i>Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada</i> • Circumventing Membrane Transporters at the Blood-Brain Barrier to Enhance Drug Delivery to the CNS <u>J.D. Unadkat</u>, <i>Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, USA</i> • Drug Metabolizing P450s within the Brain: Species and Inducer Differences <u>R.F. Tyndale</u> and S. Miksys, <i>Centre for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, Canada</i> • CYP 4Fs at the Crossroads of Endobiotic and Drug Metabolism <u>H.W. Strobel</u>, A. Kalsotra, Y. Wang, J. Bell, J. Zhao, P. Dash, Y. Kikuta, L. Du, D. Keeney, M. Duvic, <i>The University of Texas Medical School at Houston, Houston, Texas, USA</i> • Drug Resistance in Neurological Disorders <u>H. Potschka</u>, <i>Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University, Munich, Germany</i>
15:15 – 17:45	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 2000C</p> <p>S07 Towards Quality Use of Medicines Chaired by / Présidé par : Budiono Santoso, World Health Organization/WPRO, Manila, Phillippines Andrew Bate, Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, and Department of Mathematics and Computing, Brunel University, London, UK</p> <ul style="list-style-type: none"> • Irrational Use of Medicines: Global Challenges and Actions <u>K. Holloway</u>, <i>Department of Medicines Policy and Standards, World Health Organisation, Geneva, Switzerland</i> • Clinical Pharmacology and Clinical Pharmacy: Competing or Collaborating Disciplines? <u>S. Suryawati</u>, <i>Centre for Clinical Pharmacology and Medicine Policy Studies Gadjah Mada University Yogyakarta, Indonesia</i> • Challenges in Evaluating the Efficacy and Safety of Medicines for New Emerging Diseases: SARS & Avian Flu <u>S. Hill</u>, <i>World Health Organization, Geneva, Switzerland</i> • Safeguarding Patient Safety on Medicines: From Data to Useful Information <u>A. Bate</u>^{1,2}, ¹<i>Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden;</i> ²<i>Department of Mathematics and Computing, Brunel University, London, UK</i> • Involving Consumers in Promoting Safe and Effective Use of Medicines <u>B. Santoso</u>, <i>World Health Organization, Western Pacific Regional Office, Manila, Philippines</i>

15:15 – 17:45	<p>Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers</p>
	<p style="text-align: right;">SALON 2000D</p> <p>S08 The Ethics of Drug Research Chaired by / Présidé par : Gideon Koren, <i>Motherisk Program, University of Toronto, Toronto, Canada and Ivey Chair, Molecular Toxicology, University of Western Ontario, London, Canada</i> Laura Roberts, <i>Charles E. Kubly Professor and Chairman, Department of Psychiatry and Behavioral Medicine, Professor of Bioethics, Department of Population Health, Medical College of Wisconsin, Milwaukee, USA</i></p> <ul style="list-style-type: none"> • Informed Consent: Does it Exist? <u>E. Tsai</u>, <i>Queen's University, Kingston, Canada</i> • Drug Research in Children: Special Ethical Challenges <u>H. Sammons</u>, <i>University of Nottingham, Nottingham, UK</i> • Ethical Issues in Industry-Academia Collaboration <u>A.V. Levin</u>^{1,2}, ¹<i>The Hospital for Sick Children;</i> ²<i>Joint Centre for Bioethics, University of Toronto, Toronto, Canada</i> • Ethical Issues in Mental Illness Research <u>L. Roberts</u>, <i>Charles E. Kubly Professor and Chairman, Department of Psychiatry and Behavioral Medicine, Professor of Bioethics, Department of Population Health, Medical College of Wisconsin, Milwaukee, USA</i> • Ethics of Drug Research in Pregnancy <u>G. Koren</u>, <i>Motherisk Program, University of Toronto, Toronto, Canada and Ivey Chair, Molecular Toxicology, University of Western Ontario, London, Canada</i>
18:00 – 20:00	<p>Industrial Symposia – Symposiums Industriels</p>
	<p style="text-align: right;">SALON 2000A</p> <p>Model-Based Drug Development: Impact on Decision Making <i>Sponsored by / Commandité par : Pfizer</i> Chaired by / Présidé par : Supriya Sharma, <i>Therapeutic Products Directorate, Canada</i></p> <ul style="list-style-type: none"> • How Quantitative Methods in Clinical Pharmacology Enable Better Regulatory Decisions: Some Real Life Examples <u>L.J. Lesko</u>, <i>Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA</i> • A European Regulatory Perspective: Influence of Model-based Drug Development on Regulatory Decision Making <u>S. Jönsson</u> and A. Henningsson, <i>Medical Products Agency, Uppsala, Sweden</i> • Modeling and Simulation in Drug Development: A Decision Making Tool <u>P. Jacqmin</u>, <i>Exprimo NV, Mechelen, Belgium</i> • TBD Richard Lalonde, <i>Pfizer, USA</i>
	<p style="text-align: right;">SALON 2000B</p> <p>Identifying Value by Linking Clinical Pharmacology with Outcomes Research <i>Sponsored by / Commandité par : Oxford Outcomes</i></p>
	<p style="text-align: right;">SALON 2000D</p> <p>The Reimbursement Decision Puzzle: Exploring the Key Factors <i>Sponsored by / Commandité par Janssen Ortho</i></p>

07:15 – 08:15	Meet-the-Expert Sunrise Sessions Séance « Un expert rencontre les Lève-tôt »
	<p style="text-align: right;">SALON 2000A</p> <p>An Overview of the Research Value of Administrative Data from Private Drug Plans Speaker: Jamie Foley <i>Sponsored by / Commandité par : Brogan Inc.</i></p>
	<p style="text-align: right;">SALON 2000B</p> <p>Pediatric Pain - Clinical Breakthroughs in Pharmacologic Treatment Chaired by: Gideon Koren, <i>Motherisk Program, University of Toronto, Toronto, Canada and Ivey Chair, Molecular Toxicology, University of Western Ontario, London, Canada</i></p> <p><i>Sponsored by / Commandité par : Alliance for Better Medicines for Children</i></p> <ul style="list-style-type: none"> • Research and Practice Issues in Neonatal Pain Pharmacology Anna Taddio, The Hospital for Sick Children, Toronto, Canada • Pediatric Analgesia and Advances in Topical Analgesia Ran D Goldman, British Columbia Children's Hospital, Vancouver, Canada
07:30 – 18:00	<p style="text-align: right;">MAIN LOBBY / ENTRÉE PRINCIPALE</p> <p style="text-align: center;">Registration / Inscription</p>
08:30 – 09:30	<p style="text-align: right;">SALON 200AB</p> <p>Plenary / Plénière III: Innovations in the Treatment of Dyslipemias Jacques Genest McGill University Health Centre, Montréal, Canada</p>
09:30 – 09:45	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Coffee Break / Pause-café</p>
09:45 – 12:15	Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques
	<p style="text-align: right;">SALON 2000A</p> <p>S09 New Approaches in the Treatment of HIV Infection Chaired by / Présidé par : Mark A. Wainberg, McGill University AIDS Centre, Montréal, Canada Jonathan Angel, University of Ottawa and the Ottawa Health Research Institute, Ottawa, Canada</p> <ul style="list-style-type: none"> • The Potential Role of Therapeutic HIV Vaccination <u>J.B Angel</u>, <i>University of Ottawa and the Ottawa Health Research Institute, Ottawa, Canada</i> • Evaluation of HIV Drug Resistance as a Guide to Therapy <u>R. MacArthur</u>, <i>Wayne State University, Detroit, USA</i> • Side Effects and Toxicities of Antiretroviral Drugs <u>J. Falutz</u>, <i>McGill University Health Centre, Montréal, Canada</i> • Drug Resistance Differences among HIV Subtypes: A Growing Problem <u>M.A. Wainberg</u>, <i>McGill University AIDS Centre, Montreal, Quebec, Canada</i> • Co-Infections and Co-therapies: Treatment of HIV with Hepatitis B and C <u>M.B. Klein</u>, <i>McGill University Health Centre, Montreal, Canada</i>

09:45 – 12:15	<p>Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique</p>
	<p style="text-align: right;">SALON 2000B</p> <p>S10 Personalised Medicine: Pharmacogenetic Possibilities and Economic Realities Chaired by / Présidé par : Kiichiro Tsutani, The University of Tokyo, Tokyo, Japan Rashmi Shah, London, UK</p> <ul style="list-style-type: none"> • Can Regulatory Agencies Contribute to Rational Use of Drugs through Pharmacogenetics: A Regulatory Update Larry Lesko, FDA, USA • Pharmacogenetics Supporting Drug Development Pipeline Flow and Medicine Use <u>C. Spraggs</u>, GlaxoSmithKline, Harlow, UK • Pharmacogenetic Re-Evaluation of Drugs Withdrawn from the Market <u>R.R. Shah</u>, London, UK • Rational Design of Prospective Clinical Trials to Support Pharmacogenetically-Driven Prescribing: An Academic Viewpoint <u>J. Kirchheiner</u>, Universität Ulm, Ulm, Germany
09:45 – 12:15	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 2000C</p> <p>S11 Pharmacology Teaching in the Undergraduate Medical Curriculum: Is it Necessary? Chaired by / Présidé par : Simon Maxwell, Clinical Pharmacology Unit, University of Edinburgh, Scotland, UK Theo de Vries, VU University Medical Center, Amsterdam, The Netherlands</p> <ul style="list-style-type: none"> • Clinical Pharmacology in the Undergraduate Medical Curriculum – A Matter of Concern? <u>S. Maxwell</u>, Clinical Pharmacology Unit, University of Edinburgh, Scotland, UK • Improving Learning of Rational Prescribing of Medical Students <u>Th.P.G.M. de Vries</u>, M.C. Richir, VU University Medical Center, Amsterdam, The Netherlands • What do Students Need to Know about Drugs and How Should we Assess them? <u>M. Orme</u>, University of Liverpool, Liverpool, UK • Dilemma and Solution in Teaching Medical Pharmacology: What is New? <u>C.Y. Kwan</u>, Vascular Biology Research Group, Research Institute of Basic Medical Sciences, China Medical University, Taichung, Taiwan • Development of a National E-Learning Initiative in Pharmacology and Clinical Pharmacology for Undergraduate Medical Students <u>S. Shakib</u>, Royal Adelaide Hospital, Adelaide, Australia

Tuesday, July 29 / Le mardi 29 juillet	
09:45 – 12:15	Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers
	<div style="text-align: right;">SALON 2000D</div> <p>S12 Antidepressants in Pregnancy and Lactation Chaired by / Présidé par : Shinya Ito, The Hospital for Sick Children, Toronto, Canada Emilio J. Sanz, School of Medicine, University of La Laguna, La Laguna, Spain</p> <ul style="list-style-type: none"> • Risk and Benefits of Antidepressant Use during Breastfeeding <u>S. Ito</u>, <i>The Hospital for Sick Children, Toronto, Canada</i> • Intrauterine Exposures to Antidepressants <u>G. Koren</u>, <i>Motherisk Program, University of Toronto, Toronto, Canada and Ivey Chair, Molecular Toxicology, University of Western Ontario, London, Canada</i> • Perinatal Outcomes of Intrauterine SSRI Exposure <u>E.J. Sanz</u>, <i>C. De las Cuevas, School of Medicine, University of La Laguna, La Laguna, Spain</i> • Consequence of Antidepressant Discontinuation During Pregnancy Lee S. Cohen, Harvard Medical School, Massachusetts General Hospital, Boston, USA
09:45 – 12:15	<div style="text-align: right;">SALON 206AB</div> <p>S13 Challenges in African Pharmacology <i>Sponsored by / Commandité par</i> <i>BC Children's Hospital / Child & Family Research Institute</i> <i>IUPHAR</i> <i>Novartis</i> <i>F. Hoffmann-LaRoche</i></p> <p>In Memory of / Ebi Kimanani PhD - 1958 – 2005 / À la mémoire d'Ebi Kimanani, Ph.D. - 1958 – 2005</p> <p>Ebi, a biostatistician who was born in Kenya and has worked in the Pharmaceutical Industry in Montréal, succumbed to malaria, one of the diseases she was working so hard to eradicate. / Ebi, biostatisticienne originaire du Kenya a travaillé dans l'industrie pharmaceutique à Montréal avant de mourir prématurément de la malaria, cette maladie qu'elle avait tenté de contrer avec beaucoup d'efforts.</p> <p>Chaired by / Présidé par : David Ofori-Adjei, Centre for Tropical Clinical Pharmacology and Therapeutics, Accra, Ghana Stuart MacLeod, Child & Family Research Institute, Vancouver, Canada</p> <ul style="list-style-type: none"> • Challenges in African Pharmacology: An Overview <u>D. Ofori-Adjei</u>, <i>Centre for Tropical Clinical Pharmacology, University of Ghana Medical School, College of Health Sciences, University of Ghana, Legon, Accra, Ghana</i> • Challenges of Developing Traditional Medicines, Particularly for HIV/AIDS and Malaria Ossy Kasilo, World Health Organization Regional Office for Africa, Brazzaville, Republic of the Congo • Pharmacotherapy Teaching for Healthcare Providers: Rational Use of Medicines <u>A.O. Isah</u>, <i>University of Benin City, Benin City, Nigeria</i> • Dilemmas of Drug Regulation <u>R.O. Adome</u> and F.E. Kitutu, <i>Department of Pharmacy, Makerere University Faculty of Medicine, Kampala, Uganda</i> • Optimal Antiretroviral Therapy for Children Gabriel Anabwani, Botswana-Baylor Children's Clinical Center of Excellence, University of Botswana, Gaborone, Botswana
12:15 – 14:00	<div style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</div> <p style="text-align: center;">Lunch and Poster Viewing / Déjeuner et séance d'affichage</p>

Tuesday, July 29 / Le mardi 29 juillet	
14:00 – 15:00	<p style="text-align: right;">SALON 200AB</p> <p>Plenary / Plénière IV Innovations in Peripheral Analgesia <u>S.H. Ferreira</u>, <i>University of São Paulo, Faculty of Medicine of Ribeirão Preto, Department of Pharmacology, Ribeirão Preto, Brazil</i></p>
15:00 – 15:15	<p style="text-align: center;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Coffee Break / Pause-café</p>
15:15 – 17:45	<p>Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques</p>
	<p style="text-align: right;">SALON 2000A</p> <p>S14 Eicosanoid Receptors in Disease: Targets for Therapy Chaired by / Présidé par : Sylvain Chemtob, Université de Montréal, Montréal, Canada William Powell, McGill University, Montréal, Canada</p> <ul style="list-style-type: none"> Leukotrienes in Lung Innate Immunity <u>M. Peters-Golden</u>, <i>University of Michigan, Ann Arbor, USA</i> Activation of Granulocytes by 5-Oxo-ETE and Other 5-Oxo Polyunsaturated Fatty Acids <u>W.S. Powell</u>¹, C. Cossette¹, P. Patel², and J. Rokach², ¹<i>McGill University, Montréal, Canada</i>; ²<i>Florida Institute of Technology, Melbourne, USA</i> Nuclear PGE2 Receptors and Ischemic Retinopathies <u>S. Chemtob</u>, F. Gobeil, J.-S. Joyal, T. Zhu, <i>Hôpital Ste Justine, Research Center, Montréal, Canada</i> Resolvins, Protectins and their Receptors: A New Genus of Omega-3 Anti-inflammatory and Pro-resolving Mediators <u>C.N. Serhan</u>, <i>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA</i> Cyclopentenone Prostaglandins in Neurodegeneration <u>M.E. Figueiredo-Pereira</u>, <i>Hunter College of City University of New York, New York, USA</i>
15:15 – 17:45	<p>Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique</p>
	<p style="text-align: right;">SALON 2000B</p> <p>S15 Serotonin Receptors: Pharmacogenetics and Clinical Implication Chaired by / Présidé par : Bruce Pollock, The Centre for Addiction and Mental Health, Toronto, Canada Rachel Tyndale, University of Toronto, Toronto, Canada</p> <ul style="list-style-type: none"> Genetic Variation in Serotonin Receptors and its Clinical Impact on Psychotropic Drug Treatment <u>J. Kirchheiner</u>, <i>Universität Ulm, Ulm, Germany</i> Serotonin Receptors and the Pharmacogenetics of Antipsychotic Drug Action and Side Effects <u>G. Reynolds</u>, <i>Queen's University Belfast, Belfast, UK</i> Serotonin Receptor: Pharmacogenetics and Clinical Implications for Elders <u>B.G. Pollock</u>, <i>The Centre for Addiction and Mental Health, Toronto, Canada</i> Variation in Serotonin and Norepinephrine: Links Between Panic Attacks and Cardiac Risk <u>M. Esler</u>¹, M. Alvarenga¹, E. Lambert¹, C. Pier², D. Barton¹, L. Guo¹, F. Socratous¹, T. Dawood¹, G. Lambert¹, ¹<i>Baker Heart Research Institute, Melbourne, Australia</i>; ²<i>Deakin University, Melbourne, Australia</i> Serotonergic Drugs and Valvular Heart Disease <u>B.L. Roth</u>, <i>Departments of Pharmacology, Medicinal Chemistry, Psychiatry and Cancer Center, University of North Carolina at Chapel Hill Medical and Pharmacy Schools, Chapel Hill, USA</i>

15:15 – 17:45	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 2000C</p> <p>S16 Pharmacovigilance: New Approaches and Old Risks <i>(in collaboration with IsoP)</i> Chaired by / Présidé par : Giampaolo Velo, Clinical Pharmacology Unit and Reference Centre for Education and Communication within the WHO Programme for International Drug Monitoring, University of Verona, Verona, Italy Yola Moride, Université de Montréal, Montréal, Canada</p> <ul style="list-style-type: none"> • How to Balance Risks with Benefits Yola Moride, Université de Montréal, Montréal, Canada • Fatal Adherence to Treatment Guidelines P.A. Thuermann, HELIOS Klinikum Wuppertal, University Witten/Herdecke, Wuppertal, Germany • Brand New Second Hand? Pharmacovigilance in Emerging Countries A.N.O. Doodoo, University of Ghana Medical School, Accra, Ghana • New Drugs Old Problems, Old Drugs New Problems Nicolas Moore, CHU de Bordeaux, Université Victor Segalen - INSERM U657, Bordeaux, France • Ecopharmacovigilance: Why? G.P. Velo, Clinical Pharmacology Unit and Reference Centre for Education and Communication within the WHO Programme for International Drug Monitoring, University of Verona, Verona, Italy
15:15 – 17:45	<p>Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers</p>
	<p style="text-align: right;">SALON 2000D</p> <p>S17 Drug Utilisation in ICUs Chaired by / Présidée par : Deborah Cook, Canadian Critical Care Trials Group, McMaster University, Hamilton, Canada Niranjana Kissoon, Acute and Critical Care Programs, Department of Pediatrics, University of British Columbia, Vancouver, Canada</p> <ul style="list-style-type: none"> • How Common is Drug Counterfeiting? Some Insights From a Study in a Large Indian City M. Seear¹, D. Gandhi¹, R. Carr¹, A. Dayal², D. Raghavan², ¹Vancouver Children's Hospital, Vancouver, Canada; ²Apollo Hospital, Chennai, India • Low Molecular Weight Heparin Thromboprophylaxis in Critically Ill Patients with Severe Renal Insufficiency D. Cook, Canadian Critical Care Trials Group, McMaster University, Hamilton, Canada • Vasopressin Therapy in Critical Care K. Choong, McMaster Children's Hospital; Hamilton, Ontario; Canada • Administration of Antibiotics in the PICU of a Developing World Country A.C Argent, School of Child and Adolescent Health, University of Cape Town and Paediatric Intensive Care Unit, Red Cross War Memorial Children's Hospital, Cape Town, South Africa • Computerized Physician Order Entry (CPOE) in the Pediatric Intensive Care Unit N. Kissoon, Acute and Critical Care Programs, Department of Pediatrics, University of British Columbia, Vancouver, Canada

18:00 – 20:00	<p>Industrial Symposia – Symposiums Industriels</p>
	<p style="text-align: right;">SALON 2000A</p> <p>Drugs for Rare Disorders: Policy Dilemmas <i>Sponsored by / Commandité par :</i> CORD/Bayer/AstraZeneca/GlaxoSmithKline/Amgen Chaired by / Présidée par : Durhane Wong-Rieger, Canadian Organization for Rare Disorders Stuart MacLeod, University of British Columbia</p> <p>Invited Panelists / Panélistes invités:</p> <p>Doug Coyle, Department of Epidemiology and Community Medicine, University of Ottawa; Coyle Consultancy, Ottawa, Canada</p> <p>Stuart M. Macleod, Child & Family Research Institute; Department of Pediatrics, University of British Columbia, Vancouver; and Provincial Health Services Authority , Vancouver, Canada</p> <p>Devidas Menon, School of Public Health</p> <p>Norman Daniels, Harvard School of Public Health</p> <p>Marlene E. Haffner, MD, MPH Executive Director, Global Regulatory and Intelligence Policy Amgen</p> <p>Durhane Wong-Rieger, Canadian Organization for Rare Disorders</p>
	<p style="text-align: right;">SALON 2000B</p> <p>Translational Medicine and Clinical Pharmacology <i>Sponsored by / Commandité par :</i> Merck Frosst</p> <ul style="list-style-type: none"> • Molecular Imaging in Drug Discovery and Development Richard Hargreaves, Merck Research Laboratories, West Point, USA • Clinical Pharmacology & Modeling & Simulation Jeff Chodakewitz, Merck Research Laboratories, Upper Gwynedd, USA • Early Decision & Experimental Medicine Gary A. Herman, Merck Research Laboratories, Rahway, USA
	<p style="text-align: right;">SALON 2000D</p> <p>Iron Chelation Evolution: From Reduction of Total Body Excess to Organ Specific Chelation to Correction of Subcellular Iron <i>Sponsored by / Commandité par :</i> ApoPharma</p> <ul style="list-style-type: none"> • Update on Iron Chelation For Treating Iron Overload Antonio Piga, Turin, Italy • Decline in Heart Disease and Increased Survival Trends in Thalassemia Major Caterina Borgna-Pignatti, Ferrara, Italy • Assessment of Myocardial Siderosis and Evidence Based Treatment Strategies for its Prevention <u>D. Pennell</u>, <i>Royal Brompton Hospital, London, UK</i> • Iron Chelation – Exploring Potential New Benefits <u>R. Galanello</u>, <i>Dipartimento di Scienze Biomediche e Biotechnologie – Università degli Studi di Cagliari Ospedale Regionale Microcitemie – ASL8 Cagliari, Italy</i>

07:15 – 08:15	<p>Meet-the-Expert Sunrise Sessions Séance « Un expert rencontre les Lève-tôt »</p>
	<p style="text-align: right;">SALON 2000A</p> <p>Perspectives on the Evolution of Modified-release Methylphenidate Dosage Forms for the Treatment of ADHD <u>A.B. Straughn</u>, <i>University of Tennessee, Memphis, USA</i></p> <p><i>Sponsored by / Commandité par : Purdue Pharma</i></p>
07:30 – 18:00	<p style="text-align: right;">MAIN LOBBY / ENTRÉE PRINCIPALE</p> <p style="text-align: center;">Registration / Inscription</p>
08:30 – 09:30	<p style="text-align: right;">SALON 200AB</p> <p>Plenary / Plénière V: Antioxidants: Disease Prevention, Therapeutic Agents or the Epitome of Uselessness? Barry Halliwell Yong Loo Lin School of Medicine National University of Singapore, Singapore</p>
09:30 – 09:45	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Coffee Break / Pause-café</p>
09:45 – 12:15	<p>Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques</p>
	<p style="text-align: right;">SALON 2000A</p> <p>S18 Targeting Cellular Signalling: Clinical Relevancy <i>Sponsored by the Pharmacological Society of Canada / Commandité par la Société canadienne de pharmacologie</i> Chaired by / Présidé par : <u>Audrey Claing</u>, <i>Department of Pharmacology, Université de Montréal, Montréal, Canada</i> <u>Nathalie Vergnolle</u>, <i>INSERM U563, Toulouse, France</i></p> <ul style="list-style-type: none"> • Protease Signalling through G Protein-Coupled Receptors: Implications for Pain <u>N. Vergnolle</u>, <i>INSERM U563, Toulouse, France</i> • Heterogenous Neutrophil Microparticles as Effectors of Anti-inflammation and Biomarkers <u>M. Perretti</u>, <u>J. Dalli</u>, <i>William Harvey Research Institute, Barts and the London School of Medicine, London, UK</i> • G-Protein-Mediated Signalling in Vascular Physiology and Pathology <u>S. Offermanns</u>, <i>Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany</i> • Small GTPases and the Progression of Breast Cancer <u>A. Claing</u>, <u>P-L. Boulay</u>, and <u>M. Cotton</u>, <i>Department of Pharmacology, Université de Montréal, Montréal, Canada</i> • The Role of MSCs in the Prevention of Acute Kidney Injury <u>B. Bi</u>, <u>L.G. Cantley</u>, <i>Yale University School of Medicine, New Haven, USA</i>

09:45 – 12:15	<p>Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique</p>
	<p style="text-align: right;">SALON 2000B</p> <p>S19 Mechanism-based PK-PD Modeling – From Pharmacology to Clinical Practice Chaired by / Présidé par : Oscar E. Della Pasqua, Leiden-Amsterdam Center for Drug Research, Leiden, The Netherlands Nick H.G. Holford, University of Auckland, Auckland, New Zealand</p> <ul style="list-style-type: none"> • Basic PK-PD Principles of Proliferative and Circular Systems <u>P. Jacqmin</u>¹, L. McFadyen² and J.R. Wade¹, ¹<i>Exprimo NV, Mechelen, Belgium;</i> ²<i>Pharmacometrics, Pfizer Global Research and Development, Sandwich, UK</i> • TBD Oscar E. Della Pasqua, Leiden-Amsterdam Center for Drug Research, Leiden, The Netherlands • Washout of Treatment Effects is Essential for Distinguishing Short (symptomatic) and Long-term (disease modifying) Treatment Effects from Natural Disease Progression <u>B.A. Ploeger</u>^{1,2} and N.H.G. Holford³, ¹<i>LAP&P Consultants BV, Leiden, The Netherlands;</i> ²<i>Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands;</i> ³<i>Department of Pharmacology & Clinical Pharmacology, University of Auckland, Auckland, New Zealand</i> • Modeling of Tumor Progression, Anticancer Drug Effect and Simulation of Clinical Endpoints in Oncology <u>R. Bruno</u>, L. Claret, <i>Strategic Consulting Services, Pharsight Corporation, Marseille, France</i> • PKPD Model Development in Neonates and Children <u>N.H.G. Holford</u>, <i>University of Auckland, Auckland, New Zealand</i>
09:45 – 12:15	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 2000C</p> <p>S20 Cancer Pharmacogenomics Chaired by / Présidé par : Maja Krajinovic, Centre de recherche CHU Sainte-Justine, Montréal, Canada, et Département de Pharmacologie, Université de Montréal, Montréal, Canada Chantal Guillemette, Canada Research Chair in Pharmacogenomics, Laboratory of Pharmacogenomics, CHUQ Research Center and Faculty of Pharmacy, Laval University, Québec, Canada</p> <ul style="list-style-type: none"> • Advances and Perspectives in Cancer Pharmacogenetics <u>M. Eichelbaum</u>, <i>Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany</i> • Pharmacogenomics in Colon Cancer: Fantasy or Reality? <u>H.-J. Lenz</u>, <i>University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, USA</i> • Whole Genome Studies to Identify Pharmacogenomic Signatures of Anticancer Agents <u>M.E. Dolan</u>, C. Hartford, P. H. O'Donnell, S. Duan, R.S. Huang, E. Kistner, W. Zhang, <i>University of Chicago, Chicago, IL, USA</i> • Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia <u>M. Krajinovic</u>^{1,3}, S. Dulucq¹, M. Ansari¹, G. St-Onge¹, G. Sauty¹, F. Baaz¹, D. Labuda^{1,2}, D. Sinnett^{1,2}, A. Moghrabi^{1,2}, ¹<i>Centre de recherche CHU Sainte-Justine, Montréal, Canada,</i> ²<i>Département de Pédiatrie, Université de Montréal, Montréal, Canada,</i> ³<i>Département de Pharmacologie, Université de Montréal, Montréal, Canada</i> • Advances in the Pharmacogenomics of Phase II Drug Metabolizing Enzymes <u>C. Guillemette</u>, <i>Canada Research Chair in Pharmacogenomics, Laboratory of Pharmacogenomics, CHUQ Research Center and Faculty of Pharmacy, Laval University, Québec, Canada</i>

09:45 – 12:15	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 206AB</p> <p>S21 Academic Drug Trials – an Endangered Species Due to Bureaucracy and Costs? Chaired by / Présidé par : Paul Hjemdahl, Clinical Pharmacology, Karolinska Institutet, Solna, Sweden Curt D. Furberg, Wake Forest Public School of Medicine, Winston-Salem, USA</p> <ul style="list-style-type: none"> • Has Industry Created a Monopoly on Clinical Trials by Implementing Similar GCP Rules for All Studies? Brian Moulton, Irish Clinical Oncology Research Group, Dublin, Ireland • Need for Academic Trials and Hurdles to Overcome: The Swedish Perspective <u>P. Hjemdahl</u>, <i>Clinical Pharmacology, Karolinska Institutet, Solna, Sweden</i> • Need for Academic Trials and Hurdles to Overcome: The U.S. Perspective <u>C.D. Furberg</u>, <i>Wake Forest Public School of Medicine, Winston-Salem, USA</i> • Academically Sponsored Trials with GCP - The Canadian Experience <u>J.-P. Collet</u>, <i>Children's Hospital, Child and Family Research Institute, Center for Applied Health Research and Evaluation and University of British Columbia, Vancouver, Canada</i> • Towards a European Integration of Tools, Practice and Services for Academia-sponsored Trials – ECRIN, a European Solution? <u>J. Demotes-Mainard</u>, <i>ECRIN Coordination, INSERM, Paris, France</i>
09:45 – 12:15	<p>Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers</p>
	<p style="text-align: right;">SALON 2000D</p> <p>S22 Better Medicines for Children Chaired by / Présidé par : Kalle Hoppu, Poison Information Centre - Helsinki University Central Hospital, Helsinki, Finland; University of Helsinki, Helsinki, Finland Madlen Gazarian, University of New South Wales and Sydney Children's Hospital, Randwick, Sydney, Australia</p> <ul style="list-style-type: none"> • Opening Remarks / Introduction <u>K. Hoppu</u>, ¹<i>Poison Information Centre - Helsinki University Central Hospital, Helsinki, Finland</i>; ²<i>University of Helsinki, Helsinki, Finland</i> • Therapeutic Orphans for 40 Years – How and Why? Steven Hirschfeldt, National Institute of Child Health and Human Development, Bethesda, USA • Children's Access to Essential Medicines <u>S. Hill</u>, <i>World Health Organization, Geneva, Switzerland</i> • Evaluating Appropriateness of Off-label Medicines Use: Implications for Policy, Practice and Research <u>M. Gazarian</u>, <i>University of New South Wales and Sydney Children's Hospital, Randwick, Sydney, Australia</i> • Need for a New Paradigm in Regulatory Assessment of Children's Medicines <u>K. Hoppu</u>^{1,2}, ¹<i>Poison Information Centre - Helsinki University Central Hospital, Helsinki, Finland</i>; ²<i>University of Helsinki, Helsinki, Finland</i> • Redistribution of Pediatric Clinical Pharmacological Research – From Scientific to Regulatory Trials and from Developed to Developing Countries <u>G.L. Kearns</u>, <i>Departments of Pediatrics and Pharmacology, University of Missouri – Kansas City, Kansas City, MO and the Division of Pediatric Pharmacology and Medical Toxicology, Children's Mercy Hospitals and Clinics, Kansas City, USA</i>
12: 15 – 14:00	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Lunch and Poster Viewing / Déjeuner et séance d'affichage</p>

Wednesday, July 30 / Le mercredi 30 juillet	
14:00 – 15:00	<p style="text-align: right;">SALON 200AB</p> <p>Plenary / Plénière VI: Malaria Chemotherapy – In Search of Magic Bullets Giancarlo Biagini, Liverpool School of Tropical Medicine, Liverpool, UK</p>
15:00 – 15:15	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Coffee Break / Pause-café</p>
15:15 – 17:45	<p>Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques</p>
	<p style="text-align: right;">SALON 2000A</p> <p>S23 Clinical Pharmacology and Therapeutic Role of New Generation Antiepileptic Drugs (AEDs) Chaired by / Présidé par : Emilio Perucca, University of Pavia, Pavia, Italy Meir Bialer, Hebrew University, Jerusalem, Israel</p> <ul style="list-style-type: none"> The Clinical Pharmacology of New Antiepileptic Drugs (AEDs) <u>M. Bialer</u>, <i>Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel</i> New Generation vs Old Generation Antiepileptic Drugs (AEDs): Have we Gained in Efficacy and Safety? <u>E. Perucca</u>, <i>Institute of Neurology, IRCCS C Mondino Foundation, and Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy</i> New Generation vs. Old Generation AEDs: What Do We Know to Make Rational Drug Selections in Women of Childbearing Potential? <u>T. Tomson</u>, <i>Karolinska Institutet, Stockholm, Sweden</i> Are New Generation AEDs Less Involved in Drug Interactions? <u>R.H. Levy</u>, <i>University of Washington, Seattle, USA</i> Therapeutic Drug Monitoring of New Generation AEDs: Useful, Necessary, or Not Indicated? <u>S. I. Johannessen</u>, <i>The National Center for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, Norway</i>
15:15 – 17:45	<p>Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique</p>
	<p style="text-align: right;">SALON 2000B</p> <p>S24 Transporters: Relevance to Drug Disposition and Disease Chaired by / Présidé par : Richard B. Kim, <i>Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London, Ontario, Canada</i> Martin Fromm, <i>Institute of Experimental and Clinical Pharmacology and Toxicology, Clinical Pharmacology and Clinical Toxicology, Emil-Fischer-Center, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany</i></p> <ul style="list-style-type: none"> Intestinal Drug Uptake: New and Old Transporters with Novel Function <u>R.B. Kim</u>, <i>Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London, Ontario, Canada</i> OATP Transporters: Expression, Polymorphisms, and Tissue Distribution <u>M.F. Fromm</u>, <i>Institute of Experimental and Clinical Pharmacology and Toxicology, Clinical Pharmacology and Clinical Toxicology, Emil-Fischer-Center, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany</i> MRP1: Structural Basis for Activity and Substrate Selectivity <u>S.P.C. Cole</u>, <i>Queen's University Cancer Research Institute, Kingston, Canada</i> MRP4 Knockout Mouse and the Search for a Transporters Functional Relevance <u>J.D. Schuetz</u>, <i>St. Jude Children's Hospital, Memphis, USA</i> OST Alpha and Beta: Relevance to Drug Response and Bile Acid Transport <u>P.A. Dawson, J. Haywood, A. Rao</u>, <i>Wake Forest University School of Medicine, Winston-Salem, USA</i>

15:15 – 17:45	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 2000C</p> <p>S25 The Use of Quality Indicators in Therapeutics: Does it Improve Drug Prescribing? Chaired by / Présidé par : Ulf Bergman, Division of Clinical Pharmacology & Regional Adverse Drug Reaction (ADR) Centre, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Jacques LeLorier, Université de Montréal, Montréal, Canada</p> <ul style="list-style-type: none"> • Prescribing Quality Indicators: What Do We Know About their Validity and Precision? <u>M. Andersen</u>, <i>Research Unit for General Practice, University of Southern Denmark, Odense, Denmark</i> • Use of Quality Indicators for Antibiotic Prescribing <u>V. Vlahovic-Palcevski</u>, <i>University Hospital Rijeka, Rijeka, Croatia</i> • WHO Indicators Used to Assess the Quality of Drug Therapy at the National Level <u>K. Holloway</u>, <i>Department of Medicines Policy and Standards, World Health Organisation, Geneva, Switzerland</i> • Quality Indicators and Physician Pay-for-Performance: US and Australian Perspectives from a Primary Care Viewpoint <u>F. May</u>, <i>Harvard Medical School, Boston, USA</i> • Use of “Adverse Drug Reactions” in a Quality of Drug-prescribing program in Sweden <u>U. Bergman</u>, <i>Division of Clinical Pharmacology & Regional Adverse Drug Reaction (ADR) Centre, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden</i>
15:15 – 17:45	<p>Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers</p>
	<p style="text-align: right;">SALON 2000D</p> <p>S26 Drug Abuse and Dependence: The New Science for an Old Problem Symposium IUPHAR-IUTOX Chaired by / Présidé par : Edward M. Sellers, Decision-line Clinical Research, Toronto, Canada Magi Farré, IMIM-Hospital del Mar, Barcelona, Spain</p> <ul style="list-style-type: none"> • The New Epidemiology and Science of Drug Abuse Wilson Compton, National Institute on Drug Abuse, Rockville, USA • Pharmacokinetics of Drugs of Abuse Magi Farré, Universitat Autònoma de Barcelona, Barcelona, Spain • Pharmacogenetics and Drug Abuse <u>R. Tyndale</u>, <i>Centre for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, Canada</i> • Advances in Assessing Abuse Potential in Humans Edward M. Sellers, Decision-line Clinical Research, Toronto, Canada • The Internet as a Window on Drug Abuse <u>N. Scherbaum</u>, <i>H. Siemann, Rhine State Hospital, Hospital of the University Duisburg-Essen, Germany</i>

Wednesday, July 30 / Le mercredi 30 juillet

18:00 – 20:00	Industrial Symposia – Symposiums Industriels
	Pharmacokinetics and Metabolism in Early Clinical Trials SALON 202 <i>Sponsored by / Commandité par : Xceleron / Pharmaceutical Profiles</i> <ul style="list-style-type: none">• Early Human PK: Enhanced Phase I and Metabolite Profiling <u>C. Garner</u>, <i>Xceleron Inc., Germantown, USA</i>• Microdose and Microtracer Studies in Early Clinical Development <u>L. Stevens</u>, <i>Pharmaceutical Profiles, Nottingham, UK</i>• Human Microdosing in Practice: A Five-Molecule Microdose Study <u>A. Madan</u>, <i>Neurocrine Biosciences Inc., San Diego, USA</i>
18:00 – 20:00	Sponsored Special Session / Sessions spéciales commanditées
	COMPUS - The Canadian Optimal Medication Prescribing and Utilization Service SALON 2000A <i>Sponsored by / Commandité par : Canadian Agency for Drugs and Technologies in Health (CADTH)</i>

Thursday, July 31 / Le jeudi 31 juillet	
07:15 – 08:15	Meet-the-Expert Sunrise Sessions Séance « Un expert rencontre les Lève-tôt »
	SALON 206AB
	History of Insulin <i>Sponsored by / Commandité par : The Lilly Foundation</i> <i>Michael Bliss, University of Toronto, Toronto, Canada</i>
07:30 – 18:00	MAIN LOBBY / ENTRÉE PRINCIPALE
	Registration / Inscription
08:30 – 09:30	SALON 2000ABCD
	Plenary / Plénière VII: Prescribing for Pregnant Women: The Facts and the Fears <i>L.A. Magee¹⁻⁴, Departments of ¹Medicine, ²Obstetrics and Gynaecology, and ³Health Care and Epidemiology, University of British Columbia, Vancouver, Canada; ⁴Centre for Advanced Health Research and Evaluation, Child and Family Research Institute, University of British Columbia, Vancouver, Canada</i>
09:30 – 09:45	EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC
	Coffee Break / Pause-café
09:45 – 12:15	Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques
	SALON 2000A
	S27 Endothelial Dysfunction as a Therapeutic Target Chaired by / Présidé par : <i>Carlos F. Sánchez-Ferrer, Universidad Autónoma de Madrid, Madrid, Spain</i> <i>Thomas Walther, Hull York Medical School; University of Hull, UK</i> <ul style="list-style-type: none"> • Endothelium and Vascular Disease <i>C. F. Sánchez-Ferrer¹, C. Peiró¹, L. Rodríguez-Mañas², ¹Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. ²Servicio de Geriatria y Unidad de Investigación, Hospital Universitario de Getafe, ;Madrid, Spain</i> • Endothelial Cell Senescence <i>J.D. Erusalimsky, University of Wales Institute, Cardiff, UK</i> • The G Protein-coupled Receptor Mas as a New Target to Improve Endothelial Function <i>T. Walther, Hull York Medical School; University of Hull, UK</i> • Pro-inflammatory and Oxidative Mechanisms in Diabetic Endothelial Dysfunction <i>C. Peiró, C.F. Sánchez-Ferrer, Dpto. de Farmacología, Universidad Autónoma de Madrid, Madrid, Spain</i> • Targeting Soluble Guanylate Cyclase in Vascular Disease: Preservation of Cytoprotective Cyclic GMP Signalling <i>A.J. Hobbs, Department of Pharmacology, University College London, London, UK</i>

09:45 – 12:15	<p>Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique</p>
	<p style="text-align: right;">SALON 2000B</p> <p>S28 Safety and Efficacy of Herbal Medicines Chaired by / Présidé par : Thomas K.H. Chang, The University of British Columbia, Vancouver, Canada Basil D. Roufogalis, University of Sydney, Sydney, Australia</p> <ul style="list-style-type: none"> • In search of Reasons for Discrepancies in Herbal Trial Outcomes: The Case of Saw Palmetto (<i>Serenoa repens</i>). <u>P.A.G.M. De Smet</u>, H.C.H. Wollersheim, D.M. Marcus, <i>Scientific Institute of Dutch Pharmacists, The Hague, The Netherlands</i> • PPARs: Targets for Natural Products in Diabetes and Hyperlipidemia <u>B. Roufogalis</u>, T.H-W. Huang, Y. Li, <i>University of Sydney, Sydney, Australia</i> • Cancer Chemopreventive Phytochemicals Derived from Medicinal Herbs <u>Y-J. Surh</u>, <i>National Research Laboratory of Molecular Carcinogenesis and Chemoprevention College of Pharmacy, Seoul National University, Seoul, South Korea</i> • Effect of Natural Health Products on Drug Disposition <u>B.C. Foster</u>, <i>Therapeutic Products Directorate, Health Canada, Ottawa, Canada</i> • Herbal Medicines as Modulators of CAR and PXR <u>T.K. H. Chang</u>, <i>University of British Columbia, Vancouver, Canada</i>
09:45 – 12:15	<p>Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société</p>
	<p style="text-align: right;">SALON 2000C</p> <p>S29 Pharmacogenetic Epidemiology Chaired by / Présidé par : Anders Rane, Karolinska Institutet, Division of Clinical Pharmacology at Karolinska University Hospital, Stockholm, Sweden John Raelson, Genizon BioSciences, St-Laurent, Canada</p> <ul style="list-style-type: none"> • Genome Wide Association Studies Using the Quebec Founder Population <u>J. Raelson</u>, Genizon BioSciences, St-Laurent, Canada • Data Capture in Large Patient Cohorts – Selection Bias and Matching <u>A. Rane</u>, <i>Karolinska Institutet, Division of Clinical Pharmacology at Karolinska University Hospital, Stockholm, Sweden</i> • The Challenges of Design and Implementation of Whole Genome Association Studies – Phenotypes, Biobanking and Data Generation <u>N.K. Spurr</u>, <i>Roche Products Ltd, Welwyn Garden City, UK</i> • Ethnic Aspects in Pharmacogenetic Research <u>M. Schwab</u>, <i>Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany</i>

Thursday, July 31 / Le jeudi 31 juillet	
09:45 – 12:15	Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers
	<p style="text-align: right;">SALON 2000D</p> <p>S30 Geriatric Pharmacology Chaired by / Présidé par : Peter Crome, Keele University, Stoke-On-Trent, UK Steve Jackson, Department of Clinical Gerontology, King's College Hospital, London, UK</p> <ul style="list-style-type: none"> • Concordance in Older People <u>P. Crome</u>, <i>Keele University, Stoke-On-Trent, UK</i> • Old Drugs, New Drugs, Good Drugs, and Bad Drugs: Assessing Drug Use and Burden in Older Adults <u>D.M. Fick</u>, <i>The Pennsylvania State University, College of Health and Human Development, School of Nursing, and School of Medicine, University Park, USA</i> • Stroke Prevention Strategies <u>S.H.D. Jackson</u>, <i>Department of Clinical Gerontology, King's College Hospital, London, UK</i> • Drugs for Alzheimer's and How to Measure Response Ken Rockwood, Geriatric Medicine Research Unit, Halifax, Canada • Treatment of Parkinson's Disease in Older People <u>P.A.F. Jansen</u>, <i>Department of Geriatric Medicine, UMC, Utrecht, The Netherlands</i>
12:15 – 14:00	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Lunch and Poster Viewing / Déjeuner et séance d'affichage</p>
14:00 – 15:00	<p style="text-align: right;">SALON 2000ABCD</p> <p>Plenary / Plénière VIII: Public Health Implications of Research Utilizing Pharmacovigilance Databases <u>D.W.J. Clark</u>¹, <u>R.L Savage</u>², ¹<i>Department of Pharmacology & Toxicology,</i> ²<i>New Zealand Pharmacovigilance Centre, Department of Preventive & Social Medicine, University of Otago, Dunedin, New Zealand</i></p>
15:00 – 15:15	<p style="text-align: right;">EXHIBITION HALL AND FOYER 4, SALON 400 ABC / SALLE D'EXPOSITION ET FOYER 4, SALON 400 ABC</p> <p style="text-align: center;">Coffee Break / Pause-café</p>
15:15 – 17:45	Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques
	<p style="text-align: right;">SALON 2000A</p> <p>S31 Progress in Immunopharmacology Chaired by / Présidé par : Boulos Haraoui Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada William Rigby, Department of Medicine, Microbiology and Immunology, Dartmouth Medical School, Lebanon, USA</p> <ul style="list-style-type: none"> • Differentiating Features of the Anti-TNF Agents: Lessons Learned from the Clinic <u>B. Haraoui</u>, <i>Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada</i> • B Cell Targeting for Autoimmune Diseases <u>W.F.C. Rigby</u>, <i>Department of Medicine, Microbiology and Immunology, Dartmouth Medical School, Lebanon, USA</i> • T Cell Blockade In RA: An Efficient Therapeutic Strategy – Finally <u>E. Keystone</u>, <i>University of Toronto, Toronto, Canada</i> • The Relationships between Clinical Efficacy and Control of Joint Damage During Treatment With a TNF-antagonist and/or Methotrexate (MTX) in Early Rheumatoid Arthritis (RA) <u>E. H. Sasso</u>¹, <u>K. Patra</u>², ¹<i>Abbott Laboratories, Abbott Park, USA;</i> ²<i>Abbott Laboratories, Parsippany, USA</i> • TNF Blockade and Humoral Responses: Lessons from Spondyloarthritis <u>D. Baeten</u>, <i>Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands</i>

Thursday, July 31 / Le jeudi 31 juillet	
15:15 – 17:45	Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique
	<p style="text-align: right;">SALON 2000B</p> <p>S32 Clinical Relevance of Nitric Oxide (NO) and its Inhibitors Chaired by / Présidé par : Salvador Moncada, The University College London, London, UK Arnold G. Herman, University of Antwerp, Wilrijk, Belgium</p> <ul style="list-style-type: none"> • Cell Respiration and Nitric Oxide <u>S. Moncada</u>, <i>The Wolfson Institute for Biomedical Research, University College London, London, UK</i> • NO in Atherosclerosis <u>A.G. Herman</u>, <i>University of Antwerp – CDE, Antwerp, Belgium</i> • NO, Peroxynitrite and Matrix Metalloproteinases in Acute and Chronic Heart Failure <u>R. Schulz</u>, <i>Cardiovascular Research Group, University of Alberta, Edmonton, Canada</i> • NO Inhibitors in Septic Shock M. Singer, <i>Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK</i> • Estrogen Atherosclerosis: Intermediate Role of Nitric Oxide <u>G. Chaudhuri</u>¹, L. Nathan², ¹<i>Department of Molecular and Medical Pharmacology and Department of Obstetrics and Gynecology, David Geffen School of Medicine, UCLA, Los Angeles, USA,</i> ²<i>Department of Obstetrics and Gynecology, David Geffen School of Medicine, UCLA, Los Angeles, USA</i>
15:15 – 17:45	Stream 3: Medicines and Society Domaine 3 : Les médicaments et la société
	<p style="text-align: right;">SALON 2000C</p> <p>S33 Paying for Medicines - What is a Fair Price? Chaired by / Présidé par : Suzanne Hill, World Health Organization, Geneva, Switzerland Alar Irs, University of Tartu, Tartu, Estonia</p> <ul style="list-style-type: none"> • Fair Prices and Paying for Medicines- What do we Know? <u>S. Hill</u>, <i>World Health Organization, Geneva, Switzerland</i> • Medicines, Money and Economic Transition of the Eastern Europe <u>A. Irs</u>, <i>Division of Clinical Pharmacology, University of Tartu, Estonia and State Agency of Medicines, Tartu, Estonia</i> • The South African Experience with Regulating Medicine Prices <u>A. Pillay</u>, <i>National Department of Health, Pretoria, South Africa</i> • Evidence-based Drug Purchasing: 5 Years Experience of the Emilia Romagna AVEN Drug Consortium <u>N. Magrini</u>, <i>CeVEAS, NHS Centre for the Evaluation of the Effectiveness of Health Care, Modena, Italy</i> • Capturing the Full Value of Innovative Health Interventions: Pitting Health Economic Constraints against Biopharmaceutical Progress Andreas Maetzel, <i>Amgen (Europe) GmbH, Zug, Switzerland and University of Toronto, Dept. of Health Policy Management & Evaluation, Toronto, Canada</i>

15:15 – 17:45

Stream 4: Clinical Pharmacology in Special Populations
Domaine 4 : La pharmacologie clinique auprès des groupes particuliers

SALON 2000D

S34 Traditional Chinese Medicine (TCM): A Global Approach

Chaired by / Présidé par :

Michael J. Rieder, CIHR-GSK Chair in Paediatric Clinical Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada
 Yung-Chi Cheng, Yale University School of Medicine, New Haven, USA

- The Consortium for the Globalization of Chinese Medicine – Objectives and Accomplishments
Y.-C. Cheng, *Yale University School of Medicine, New Haven, USA*
- Standardization of TCM Preparations for Global Use – Chemical Fingerprinting
 Guoan Luo, *Tsinghua University, Beijing, China*
- Application of Genomics and Cell Signaling Technologies to Investigate Traditional Chinese Medicine: Mechanisms of the Immunomodulatory Effects of Ginseng
 D.C.W. Lee², S.C.C. Chik¹, J.C.B. Li^{1,2}, C.L. Yang^{1,2}, P.K.H. Tam¹, A.S.Y. Lau^{1,2}, ¹*Molecular Chinese Medicine Laboratory and* ²*Immunology Research Lab-Paediatrics, LKS Faculty of Medicine, University of Hong Kong, Hong Kong*
- High-throughput Screening of Chemicals for Blockade of the Dioxin Pathway in Traditional Chinese Medicine
M. Kitamura, *Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan*
- Complementary Therapy with TCM and their Constituents
M. Rieder, *CIHR-GSK Chair in Paediatric Clinical Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada*
- Concluding Comments
 Jack Bend, *University of Western Ontario, London, Canada*

19:00 – 22:00

Fun Night: Let the circus entertain you! / Soirée de divertissement : Laissez-vous emporter par le cirque!

Friday, August 1 / Le vendredi 1er août	
07:30 – 12:00	MAIN LOBBY / ENTRÉE PRINCIPALE Registration / Inscription
08:30 – 09:30	SALON 200AB Plenary / Plénière IX: Contribution of Pharmacogenomics to Improved Outcomes of Drug Therapy: Focus on the Latest Developments <i>Sponsored by the Pharmacological Society of Canada / Commandité par la Société canadienne de pharmacologie</i> <u>R. Weinsztilboun</u> , Mayo Clinic, Rochester, USA
09:45 – 12:15	Stream 1: New Therapeutic Approaches Domaine 1 : Nouvelles approches thérapeutiques
	SALON 2000A S35 Prevention of Left Ventricular Hypertrophy (LVH) and Cardiac Remodelling: Beyond Blood Pressure Reduction Chaired by / Présidé par : Rebecca Ritchie, Baker Heart Research Institute, Melbourne, Australia David A. Kass, Johns Hopkins Medical Institutions, Baltimore, USA <ul style="list-style-type: none"> • The Interaction Between the Endothelium and the Myocardium is a Controlling Mechanism of Abnormal Cardiac Growth <u>R.H. Ritchie</u>, Baker Heart Research Institute, Melbourne, Australia • Neurohormonal Control of Pathological Hypertrophy and Fibrosis <u>Y. Sun</u>, University of Tennessee Health Science Center, Memphis, USA • Do all Antihypertensive Agents Effectively Reduce LVH, and If Not Why Not? Richard Devereux, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, USA • Optimal Assessment of LVH Regression in Clinical Trials: Pros and Cons of Echocardiography, MRI and Tissue Doppler <u>M. Vogel</u>, Kinderherzpraxis, Deutsches Herzzentrum, Munich, Germany • Does Viagra Offer New Hope for Regression of LVH: Basic Pharmacology Providing Insight for Future Clinical Trial Directions David A. Kass, Johns Hopkins Medical Institutions, Baltimore, USA
09:45 – 12:15	Stream 2: From Fundamental to Clinical Pharmacology Domaine 2 : De la pharmacologie fondamentale à la pharmacologie clinique
	SALON 2000B S36 Brain Imaging and Clinical Pharmacology: Scientific Innovation in Future Drug Development Chaired by / Présidé par : Kazuhiko Yanai, Tohoku University School of Medicine, Sendai, Japan Dean F. Wong, Johns Hopkins Medical Institutions, Baltimore, USA <ul style="list-style-type: none"> • Molecular Imaging: Tool to Explore Pathophysiology and to Enhance Drug Development <u>D. Wong</u>, Johns Hopkins University School of Medicine, Baltimore, USA • Synthesis and <i>In Vivo</i> Evaluation of Novel Radiotracers for PET Imaging <u>N. Vasdev</u>^{1,2}, ¹PET Centre, Centre for Addiction and Mental Health, Toronto, Canada, ²Department of Psychiatry, University of Toronto, Toronto, Canada • The Prospects of Neuroimaging for Early Detection in Alzheimer's Disease <u>V.L. Villemagne</u>^{1,2}, K.E. Pike^{1,2}, M.T. Fodero-Tavoletti^{3,4}, U. Ackermann¹, K. Ellis⁵, H.J. Tochon-Danguy¹, G. O'Keefe¹, D. Ames⁶, C.L. Masters^{2,4}, C.C. Rowe¹, ¹Department of Nuclear Medicine and Centre for PET, Melbourne, Australia, ²The Mental Health Research Institute of Victoria, Melbourne, Australia, ³Bio21 Molecular and Biotechnology Institute, University of Melbourne, Melbourne, Australia, ⁴Department of Pathology, University of Melbourne, Melbourne, Australia, ⁵Department of Psychiatry, University of Melbourne, Melbourne, Australia, ⁶National Ageing Research Institute, Melbourne, Australia • PET Evaluation of Sedative Properties of Antihistamines <u>K. Yanai</u>^{1,2}, N. Okamura¹, M. Tashiro², ¹Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan; ²Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan

09:45 – 12:15

Stream 3: Medicines and Society
Domaine 3 : Les médicaments et la société

SALON 2000C

S37 Better Access to Essential Medicines : Update on Recent Developments

Chaired by / Présidé par :

Hans V. Hogerzeil, Department of Medicines Policy and Standards, World Health Organization, Geneva, Switzerland

Margaret Ewen, Health Action International, Amsterdam, The Netherlands

- Promoting Innovation through Evidence-Based Selection of Essential Medicines
M.M. Reidenberg, *Weill Cornell Medical College, New York, USA*
- Promoting Access through the World Health Organization Prequalification Program
 Lembit Rago, World Health Organization, Geneva, Switzerland
- The Availability and Affordability of Essential Medicines Across the Globe
M. Ewen, *Health Action International, Amsterdam, The Netherlands*
- Public Procurement Databases Provide Insight into Strategies to Increase Access to Antiretroviral Medicines in Low Resource Settings
B. Waning, W. Kaplan, *Boston University School of Public Health, Boston, USA*
- Improving Access to Essential Medicines through the WHO Prequalification Programme
H.V. Hogerzeil, L. Rago, *Department of Medicines Policy and Standards, WHO, Geneva, Switzerland*

09:45 – 12:15

Stream 3: Medicines and Society
Domaine 3 : Les médicaments et la société

SALON 2000D

S38 Pharmacoepidemiologic Studies as a Decision Support Tool for Regulatory Agencies, Physicians, and Patients

Sponsored by / Commandité par Le Réseau québécois de recherche sur l'usage des médicaments (RQRUM)

Chaired by / Présidé par :

Anick Bérard, Centre de recherche, CHU Ste-Justine, Montréal, Canada

Susana Pérez-Gutthann, RTI Health Solutions, Barcelona, Spain

- Health Canada and Drug Safety
M. Berthiaume, *Health Canada, Ottawa, Canada*
- The FDA and Drug Safety
S. Iyasu, *The US Food and Drug Administration, Silver Spring, USA*
- Risk Management and Epidemiology in Pharmaceutical Companies
S. Perez-Gutthann, *RTI Health Solutions, Barcelona, Spain*
- Impact of Statin Adherence on Cardiovascular Outcomes among Patients Newly Treated for Primary Prevention
S. Perreault, *Faculty of Pharmacy, Université de Montréal, Montreal, Canada*
- Risk Management Strategies to Increase Drug Safety: The Example of Isotretinoin
A. Bérard, *Centre de recherche, CHU Ste-Justine, Montréal, Canada*

09:45 – 12:15	<p>Stream 4: Clinical Pharmacology in Special Populations Domaine 4 : La pharmacologie clinique auprès des groupes particuliers</p>
	<p style="text-align: right;">SALON 206AB</p> <p>S39 Ethnic Differences in Drug Therapy Chaired by / Présidé par : Ingolf Cascorbi, University Hospital Kiel, Kiel, Germany Guilherme Suarez-Kurtz, National Cancer Institute, Rio de Janeiro, Brazil</p> <ul style="list-style-type: none"> • Anti-hypertensive Treatment in Different Ethnicities <u>B.J. Materson</u>, <i>University of Miami Miller School of Medicine, Miami, USA</i> • Ethnicity and Psychopharmacotherapy <u>W.B. Lawson</u>, <i>Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine and Hospital, Washington, USA</i> • Genetic Diversity of Drug Transporters: Relevance for Drug Therapy and Clinical Outcome <u>I. Cascorbi</u>, <i>Institute of Pharmacology, University Hospital Schleswig-Holstein, University of Kiel, Kiel, Germany</i> • Pharmacogenetics in Admixed Populations <u>G. Suarez-Kurtz</u>, <i>Instituto Nacional de Câncer, Rio de Janeiro, Brazil</i> • Pharmacogenetics and Ethnicity: The Regulator's View <u>A. Breckenridge</u>, <i>Medicines and Healthcare Products Regulatory Agency, London, UK</i>
12:15 – 13:15	<p style="text-align: right;">200AB</p> <p>Plenary / Plénière X – Closing Ceremony / Cérémonie de clôture : Future of Research in Pharmacology Salvador Moncada University College London, London, UK</p>